Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer A Meta-analysis

被引:23
|
作者
Song, Xinghua [1 ,2 ]
Meng, Zhaowei [1 ]
Jia, Qiang [1 ]
Zhang, Linlin [3 ]
Xu, Ke [4 ]
Tan, Jian [1 ]
Zhang, Guizhi [1 ]
Zheng, Wei [1 ]
Li, Xue [1 ]
Zhang, Jianping [1 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Dept Nucl Med, Tianjin 300052, Peoples R China
[2] Zhejiang Med Univ, Affiliated Hosp 2, Dept Nucl Med, Hangzhou, Zhejiang, Peoples R China
[3] Tianjin Med Univ, Gen Hosp, Dept Oncol, Tianjin 300052, Peoples R China
[4] Tianjin Med Univ, Gen Hosp, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin 300052, Peoples R China
关键词
RANDOMIZED CLINICAL-TRIAL; POSTOPERATIVE ABLATION; CARCINOMA; I-131; TISSUE;
D O I
10.1097/RLU.0000000000000914
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Remnant thyroid ablation is crucial in the management of patients with differentiated thyroid cancer. However, the optimal dose of radioactive I-131 for ablation is still controversial. This study aimed to compare the success rate of different activities of I-131 for postoperative remnant ablation in randomized controlled trials (RCTs) and to determine the optimal dose. Patients and Methods Sources were retrieved from the Cochrane Library, Medline, Embase, Scopus, and Google Scholar until March 2014. All RCTs that assessed the efficacy of different doses of I-131 for ablation were selected. After data extraction, statistics were performed by Review Manager 5.2 software. Results Seventeen RCTs were considered eligible, involving 3737 patients. The overall methodological quality of the studies was good. The rate of successful remnant ablation of low versus moderate I-131 activities (risk ratio [RR], 0.89; 95% confidence interval [CI], 0.80-1.00; P = 0.06) and moderate versus high I-131 activities (RR, 0.94; 95% CI, 0.89-1.00; P = 0.05) showed no significant differences. However, high I-131 activities had 11% higher successful ablation rate than low activities with an RR of 0.89 (95% CI, 0.81-0.97; P = 0.008), which was significant. Conclusions We summarized all available randomized evidence to demonstrate that high dose of I-131 was significantly better than low dose to achieve successful remnant thyroid ablation.
引用
收藏
页码:774 / 779
页数:6
相关论文
共 50 条
  • [21] Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma
    Frederik A. Verburg
    Markus Dietlein
    Michael Lassmann
    Markus Luster
    Christoph Reiners
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [22] Editorial: Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation
    Haugen, BR
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08): : 3665 - 3667
  • [23] Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma
    Verburg, Frederik A.
    Dietlein, Markus
    Lassmann, Michael
    Luster, Markus
    Reiners, Christoph
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (03) : 343 - 346
  • [24] A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer
    Flux, Glenn D.
    Haq, Masud
    Chittenden, Sarah J.
    Buckley, Susan
    Hindorf, Cecilia
    Newbold, Kate
    Harmer, Clive L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (02) : 270 - 275
  • [25] A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer
    Glenn D. Flux
    Masud Haq
    Sarah J. Chittenden
    Susan Buckley
    Cecilia Hindorf
    Kate Newbold
    Clive L. Harmer
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 270 - 275
  • [26] Thyroid Remnant Dose: 124I-PET/CT Dosimetric Comparison of rhTSH versus Thyroid Hormone Withholding Before Radioiodine Remnant Ablation in Differentiated Thyroid Cancer
    Freudenberg, L. S.
    Froemke, C.
    Petrich, T.
    Marlowe, R. J.
    Koska, W. W.
    Brandau, W.
    Eising, E. G.
    Knust, E. J.
    Bockisch, A.
    Jentzen, W.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2010, 118 (07) : 393 - 399
  • [27] Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
    Pitoia, Fabian
    Marlowe, Robert J.
    Abelleira, Erika
    Faure, Eduardo N.
    Bueno, Fernanda
    Schwarzstein, Diego
    Julio Lutfi, Ruben
    Niepomniszcze, Hugo
    JOURNAL OF THYROID RESEARCH, 2012, 2012
  • [28] Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros
    Ain, Kenneth B.
    ENDOCRINE, 2015, 50 (01) : 61 - 66
  • [29] Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros
    Kenneth B. Ain
    Endocrine, 2015, 50 : 61 - 66
  • [30] Radioiodine low-dose for remnant ablation in differentiated thyroid carcinoma: considerations of a pilot study
    Burroni, L.
    Castagna, M. G.
    Cipri, C.
    Pacini, F.
    Vattimo, A. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S421 - S421